Has anyone figured out using an estimated 25 people passed
Has anyone figured out using an estimated 25 people passed in the critical 62 which would be patient population. We had last known of 87 total deaths. So 62 good estimate of # that passes if we use 25% mortality in the severe out of the remaining 330 patients it would be broken down into the following
110/ SOC
220/ Leronlimab
If we use 24% which is very conservative of other trials that gives the placebo/SOC them 27 deaths that leaves the leronlimab group of 220 with 33 deaths.
33/220 = 15%
Vs
27/110 = 24.5%
This would be statistically significant endpoint met. Even in the worst case scenario which would be that there was zero effect of leronlimab vs placebo it would even split and we would still have all the amazing data from criticals. If there was zero effect however the DSMC would have shit us down for having no effectiveness. If there wasn’t a good mortality decrease overall we would have been told to add hundreds of more patients to the entire trail. I believe we have much better chance of showing good data in the severe than bad. The shorts are out there in full force trying to state otherwise but they will not give you logical reasons ans estimates like I just did. Matter in fact I don’t see anyone trying to make sense of the severe data not being reported. If it was bad or not good it needs to be released however if it is really good maybe fda asked them to hold off until they are closer to giving EUA. If anyone has better logical estimates of the severe population please post or message me. It’s like most people have completely forgot many people pass away from severe pretty quickly and that leronlimab when given earlier than peoples death beds should actually be more effective than critical not less.
5
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....
Continue Reading
Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...
Continue Reading
Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...
Continue Reading
Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...
Continue Reading
A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...
Continue Reading
When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...
Continue Reading
Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...
Continue Reading
Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...
Continue Reading
ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...
Continue Reading
Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...
Continue Reading
Top 5 Most Recently Viewed Articles
Buena Vida y Salud ACO Achieves National Recognition Buena Vida y Salud ACO has garnered significant acclaim as a recipient of the prestigious 2024 NAACOS Excellence Awards. This recognition highlights the organization's successful dedication to value-based care, shaping effective healthcare solutions tailored for patient needs. Leadership and Commitment to...
Continue Reading
SSCP Lager Bidco AB Shares Insights in Quarterly Report Introduction to the Interim Report SSCP Lager Bidco AB (publ) recently released an interim report detailing the developments from April 1 to June 30 of a specific year, highlighting significant milestones and financial performance. Key Highlights of the Interim Report In this latest report, SSCP Lager Bidco AB...
Continue Reading
Update on the Resolutions of ForFarmers N.V. Annual General Meeting In a recent communication regarding the resolutions from the Annual General Meeting of Shareholders at ForFarmers N.V., some critical information was initially misstated. This announcement focuses on clarifying these details to ensure transparency and keep our stakeholders well-informed. Corrections to...
Continue Reading
U.S. House Prices Show Remarkable Growth The latest data reveals that U.S. single-family house prices experienced a strong increase in September, presenting challenges for many potential homeowners due to rising costs. This upward trend in the housing market is noteworthy, particularly as mortgage rates have begun to climb. Monthly Price Adjustments According to the...
Continue Reading
Upbeat BidCo Raises Its Public Buyout Offer for Believe In an exciting development for investors, Upbeat BidCo has decided to increase its public buyout offer for Believe to 17.20 euros per share. This decision reflects a commitment to maximizing shareholder value while ensuring the future growth of Believe, a prominent digital music company. Significant Premium on the...
Continue Reading